<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Endocr Disord</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Endocr Disord</journal-id>
      <journal-title-group>
        <journal-title>BMC Endocrine Disorders</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1472-6823</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24884994</article-id>
      <article-id pub-id-type="pmc">4024625</article-id>
      <article-id pub-id-type="publisher-id">1472-6823-14-42</article-id>
      <article-id pub-id-type="doi">10.1186/1472-6823-14-42</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Increased expression of ACTH (<italic>MC2R</italic>) and androgen (<italic>AR</italic>) receptors in giant bilateral myelolipomas from patients with congenital adrenal hyperplasia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Almeida</surname>
            <given-names>Madson Q</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>madsonalmeida@usp.br</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Kaupert</surname>
            <given-names>Laura C</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>laukau@ig.com.br</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Brito</surname>
            <given-names>Luciana P</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>lucpbrito@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Lerario</surname>
            <given-names>Antonio M</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>amlerario@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Mariani</surname>
            <given-names>Beatriz M P</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>beatriz_galuzzi@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Marta</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>martinha_ribeiro@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Monte</surname>
            <given-names>Osmar</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>osmarmonte@uol.com.br</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Denes</surname>
            <given-names>Francisco T</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>ftdenes@terra.com.br</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Mendonca</surname>
            <given-names>Berenice B</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>beremen@usp.br</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A10">
          <name>
            <surname>Bachega</surname>
            <given-names>T&#xE2;nia ASS</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tbachega@usp.br</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Divis&#xE3;o de Endocrinologia e Metabologia, Laborat&#xF3;rio de Horm&#xF4;nios e Gen&#xE9;tica Molecular/LIM42, Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo, Av. Dr. En&#xE9;as de Carvalho Aguiar, 155, 2 andar, Bloco 6, S&#xE3;o Paulo, SP 05403-900, Brasil</aff>
      <aff id="I2"><label>2</label>Instituto do C&#xE2;ncer do Estado de S&#xE3;o Paulo (ICESP), Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, Brasil</aff>
      <aff id="I3"><label>3</label>Unidade de Endocrinologia e Metabologia, Departamento de Cl&#xED;nica M&#xE9;dica, Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo, Brasil</aff>
      <aff id="I4"><label>4</label>Servi&#xE7;o de Urologia, Hospital das Cl&#xED;nicas, Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, Brasil</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>5</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <fpage>42</fpage>
      <lpage>42</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>5</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Almeida et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Almeida et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1472-6823/14/42"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Although chronic adrenocorticotropic hormone (ACTH) and androgen hyperstimulation are assumed to be involved in the pathogenesis of adrenal myelolipomas associated with poor-compliance patients with congenital adrenal hyperplasia (CAH), the expression of their receptors has not yet been demonstrated in these tumors so far.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We analyzed <italic>Melanocortin 2 receptor</italic> (<italic>MC2R</italic>)<italic>, Androgen Receptor (AR), Leptin</italic> (<italic>LEP</italic>)<italic>,</italic> and <italic>Steroidogenic factor 1</italic> (<italic>SF1</italic>) expression using real-time qRT-PCR in two giant bilateral adrenal myelolipomas from two untreated simple virilizing CAH cases and in two sporadic adrenal myelolipomas. In addition, the X<bold>-</bold>chromosome inactivation pattern and CAG repeat number<bold>s</bold> in <italic>AR</italic> exon 1 gene were evaluated in the 4 cases.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The <italic>MC2R</italic> gene was overexpressed in myelolipomas from 3 out of 4 patients. <italic>AR</italic> overexpression was detected in 2 tumors: a giant bilateral myelolipoma in a CAH patient and a sporadic case. Simultaneous overexpression of <italic>AR</italic> and <italic>MC2R</italic> genes was found in two of the cases. Interestingly, the bilateral giant myelolipoma associated with CAH that had high androgen and ACTH levels but lacked <italic>MC2R</italic> and <italic>AR</italic> overexpression presented a significantly shorter <italic>AR</italic> allele compared with other tumors. In addition, X-chromosome inactivation pattern analysis showed a polyclonal origin in all tumors, suggesting a stimulatory effect as the trigger for tumor development.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>These findings are the first evidence for <italic>MC2R</italic> or <italic>AR</italic> overexpression in giant bilateral myelolipomas from poor-compliance CAH patients.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Adrenal myelolipoma</kwd>
        <kwd>Congenital adrenal hyperplasia</kwd>
        <kwd>ACTH</kwd>
        <kwd>
          <italic>MC2R</italic>
        </kwd>
        <kwd>Androgen receptor</kwd>
        <kwd>Clonality analysis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Adrenal myelolipomas are benign non-functioning tumors composed of adipose tissue and hematopoietic elements resembling bone marrow [<xref ref-type="bibr" rid="B1">1</xref>]. These tumors account for up to 8% of adrenal incidentalomas [<xref ref-type="bibr" rid="B2">2</xref>]. Adrenal myelolipomas are usually asymptomatic but can cause compressive symptoms. Typically, they have a fat signal intensity on T<sub>1</sub>-weighted magnetic resonance (RM) [<xref ref-type="bibr" rid="B2">2</xref>]. Interestingly, myelolipomas have been described in the setting of adrenocorticotropic hormone (ACTH) excess, such as classical congenital adrenal hyperplasia (CAH) [<xref ref-type="bibr" rid="B1">1</xref>], Cushing disease [<xref ref-type="bibr" rid="B3">3</xref>] and Nelson syndrome [<xref ref-type="bibr" rid="B4">4</xref>]. Recently, Nermoen et al. [<xref ref-type="bibr" rid="B5">5</xref>] reported a 4% frequency of adrenal myelolipomas (4 out of 101; 3 of them with bilateral myelolipomas) in a large group of unselected patients with 21-hydroxylase deficiency (21OH). Adrenal myelolipomas can rarely present as giant bilateral masses, but approximately 14 cases of giant bilateral myelolipomas have been described in association with CAH [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p>
      <p>Several mechanisms have been proposed to explain the pathogenesis of adrenal myelolipomas, such as embryonic bone marrow rests in adrenal tissue, adrenal embolization of bone marrow cells and metaplasia of adrenocortical cells [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Although chronic ACTH hyperstimulation is thought to be involved in the pathogenesis of adrenal myelolipomas based primarily on the finding of bilateral tumors in poor-compliance CAH patients, this hypothesis remains to be confirmed. <italic>Melanocortin 2 receptor (MC2R)</italic> is selectively activated by ACTH and encodes a G-protein coupled receptor. Indeed, <italic>MC2R</italic> and <italic>androgen receptor</italic> (<italic>AR</italic>) expression was previously evaluated in a single case of giant bilateral myelolipoma in a CAH patient and was negative using a semi-quantitative approach [<xref ref-type="bibr" rid="B1">1</xref>]. However, considering the high frequency of association between giant bilateral myelolipomas and CAH, we hypothesized that <italic>ACTH</italic> and <italic>AR</italic> might have a role in the pathogenesis of myelolipomas.</p>
      <p>In this study, we analyzed <italic>MC2R</italic> and <italic>AR</italic> expression as well as nCAG <italic>AR</italic> repeat numbers in two bilateral giant myelolipomas from CAH patients and two unilateral sporadic myelolipomas. Additionally, clonality was evaluated through X-chromosome inactivation analysis. Our data indicated that <italic>MC2R</italic> and/or <italic>AR</italic> were involved in the pathogenesis of myelolipomas associated with CAH, suggesting a stimulatory hormonal effect as a trigger for tumor growth. These findings are the first evidence for ACTH and androgen roles in giant bilateral myelolipomas in CAH patients and sporadic cases.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>The study was approved by the Ethics Committee of Hospital das Cl&#xED;nicas, S&#xE3;o Paulo University and from Santa Casa de Misericordia Hospital, and informed written consent was obtained from all patients for participate in the study and for the publication of data and/or images. Blood and tissue samples were collected from the patients after informed consent was obtained. Four patients with myelolipomas were evaluated in this study: two giant bilateral adrenal myelolipomas from two untreated simple virilizing CAH cases and two sporadic adrenal myelolipomas. Abdominal masses were identified with computed tomography (CT) or magnetic resonance imaging (MRI), and pathology confirmed myelolipoma after bilateral or unilateral adrenalectomy.</p>
      <sec>
        <title>Quantitative real-time PCR</title>
        <p>After surgical resection, tumor fragments were immediately frozen in liquid nitrogen and stored at -80&#xB0;C until total RNA extraction using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was generated using a High Capacity kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR (qRT-PCR) was performed with an ABI Prism 7700 sequence detector using TaqMan gene expression assays (Applied Biosystems, Foster City, CA). The assay identifications were the following: <italic>MC2R</italic> (Hs00265039_s1), <italic>AR</italic> (Hs00907244_m1), <italic>SF1</italic> (Hs00610436_m1) and <italic>LEP</italic> (Hs01084494_m1). <italic>Beta-actin</italic> (<italic>ACTB</italic>) and <italic>Glyceraldehyde-3-phosphate dehydrogenase</italic> (<italic>GAPDH</italic>) genes were used as endogenous genes. A commercial pool of adipose tissue and adrenal tissue was used for comparisons (CLONTECH, BioChain, and Ambion). Relative quantification was performed using the 2<sup>-&#x394;&#x394;CT</sup> method [<xref ref-type="bibr" rid="B12">12</xref>]. Overexpression was defined as a two-fold change in comparison to normal adipose tissue.</p>
      </sec>
      <sec>
        <title>X-Chromosome inactivation and CAG repeat numbers of the <italic>AR</italic> gene</title>
        <p>Genomic DNA was obtained from tumors using standard procedures. The X-chromosome inactivation pattern and CAG repeat numbers were determined as previously described [<xref ref-type="bibr" rid="B13">13</xref>]. Briefly, PCR amplification of the CAG repeat region of <italic>HpaII-</italic>digested and undigested samples was carried out using primers flanking the region of interest: 5&#x2019;-GCTGTGAAGGTTGCTGTTCCTC-3&#x2019; and 5'-HEX-GTGCGCGAAGTGATCCAGAA-3&#x2019;. All samples were separately amplified in 50&#xA0;&#x3BC;L reactions containing 1x PCR reaction buffer with 1.5&#xA0;mM of MgCl<sub>2</sub>, 200&#xA0;&#x3BC;M of deoxynucleotides, 15 pmol of each primer and 1 U of Taq DNA Polymerase (Amersham-Pharmacia, Uppsala, Sweden). Amplifications were performed under the following conditions: initial denaturation at 97&#xB0;C for 5&#xA0;min; amplification for 35&#xA0;cycles with denaturation at 97&#xB0;C for 1&#xA0;min, annealing at 54&#xB0;C for 45&#xA0;s and extension at 72&#xB0;C for 45&#xA0;s; and one final extension at 72&#xB0;C for 30&#xA0;min. Two and 4&#xA0;&#x3BC;L of PCR products from undigested and digested samples, respectively, were submitted to capillary electrophoresis on ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and analyzed by GeneScan software to determine the sizes of the amplified fragments, which were established through comparison<bold>s</bold> with a size marker and a sample with a known CAG repeat number in the same run. These sizes were correlated with CAG repeat numbers, as previously shown in our lab [<xref ref-type="bibr" rid="B14">14</xref>]. Digested and undigested samples were also assayed in the same run, and the peak height of each allele was used to determine the X-chromosome inactivation pattern.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <sec>
        <title>Clinical data</title>
        <p><bold>Patient 1</bold> was a 35-yr-old woman who presented with the simple virilizing form of CAH [p.E351V and exon 6 cluster (p.I236N, p.V237E, and p.M239K) mutations in a compound heterozygote state in the <italic>CYP21A2</italic> gene]. CT scan revealed giant bilateral adrenal myelolipomas (left, 14 &#xD7; 14 &#xD7; 10&#xA0;cm; right 8.9 &#xD7; 8.3 &#xD7; 8.0&#xA0;cm) with fat component density. She did not present to clinical follow-up and had not received any medications in the last 15&#xA0;yr. Hormonal evaluation revealed extremely increased levels: basal 17OH-progesterone (17-OHP) 192&#xA0;ng/mL, ACTH 1,172&#xA0;pg/mL, total testosterone 949&#xA0;ng/dL and androstenedione 17&#xA0;ng/mL (Figures&#xA0;<xref ref-type="fig" rid="F1">1</xref>A and <xref ref-type="fig" rid="F1">1</xref>B).</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold>Imaging and histopathology of giant bilateral myelolipomas in patients with congenital adrenal hyperplasia.</bold> Patient 1: <bold>A,</bold> CT scan showing heterogeneous bilateral myelolipomas (left, 14 &#xD7; 14 &#xD7; 10&#xA0;cm; right 8.9 &#xD7; 8.3 &#xD7; 8.0&#xA0;cm). <bold>B,</bold> Macroscopic aspect of left adrenal myelolipomas. Patient 2: <bold>C,</bold> CT scan revealing large bilateral myelolipomas (left, 16 &#xD7; 13 &#xD7; 9.0&#xA0;cm; right, 5.3x 4.3x 6.9&#xA0;cm). <bold>D,</bold> Macroscopic appearance of left adrenal myelolipomas.</p>
          </caption>
          <graphic xlink:href="1472-6823-14-42-1"/>
        </fig>
        <p><bold>Patient 2</bold> was a 52-yr-old woman who presented with the simple virilizing form of CAH (IVS2-13A/C&#x2009;&gt;&#x2009;G/ p.I172N). CT scan revealed giant bilateral adrenal myelolipoma (left, 16 &#xD7; 13 &#xD7; 9.0&#xA0;cm; right, 5.3 &#xD7; 4.3 &#xD7; 6.9&#xA0;cm) with fat component density (Figures&#xA0;<xref ref-type="fig" rid="F1">1</xref>C and <xref ref-type="fig" rid="F1">1</xref>D). This patient had never been previously treated, and hormonal evaluation also revealed increased serum levels: 17-OHP 120&#xA0;ng/mL, total testosterone 720&#xA0;ng/dL and androstenedione 39&#xA0;ng/mL. ACTH measurement was not available. Both CAH patients were severely virilized during adolescence and changed to male social sex. They sought medical assistance due to abdominal pain.</p>
        <p><bold>Patient 3 (a 48-yr-old female) and patient 4 (a 40-yr-old female)</bold> presented with incidental findings of sporadic unilateral adrenal myelolipoma ranging from 8 to 10&#xA0;cm in the major diameter. MRI demonstrated fat tissue signal in both masses. The patients did not present any clinical presentation of hyperandrogenism and non-classical CAH was rule-out by clinical evaluation.</p>
        <p>Briefly, the histopathological analysis of all tumors showed lobes of mature adipose tissue mixed with abundant hematopoietic tissue consisting of all three hematopoietic elements with mature and precursor cells. There were islets of cells from the zones of the adrenal cortex in the periphery of tumors as well as between hematopoietic and lipoid cells.</p>
      </sec>
      <sec>
        <title>Expression study</title>
        <p>The <italic>MC2R</italic> gene was overexpressed in the myelolipomas of 3 out of 4 patients (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>). <italic>MC2R</italic> expression was correlated with <italic>SF1</italic> mRNA levels in the same tumors. Only the myelolipoma diagnosed in patient 1 did not show <italic>MC2R</italic> overexpression. As expected, <italic>MC2R</italic> mRNA levels were higher in the adrenal pool.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>
              <bold>nCAG repeat numbers and </bold>
              <bold>
<italic>AR, MC2R, LEP </italic>
</bold>
              <bold>and </bold>
              <bold>
<italic>SF1 </italic>
</bold>
              <bold>gene expression in myelolipomas</bold>
            </p>
          </caption>
          <table frame="hsides" rules="groups" border="1">
            <colgroup>
              <col align="left"/>
              <col align="center"/>
              <col align="center"/>
              <col align="center"/>
              <col align="center"/>
              <col align="center"/>
            </colgroup>
            <thead valign="top">
              <tr>
                <th align="left">
                  <bold>Patients</bold>
                </th>
                <th align="center">
                  <bold>nCAG</bold>
                </th>
                <th align="center">
                  <bold>
<italic>AR*</italic>
</bold>
                </th>
                <th align="center">
                  <bold>
<italic>MC2R*</italic>
</bold>
                </th>
                <th align="center">
                  <bold>
<italic>LEP*</italic>
</bold>
                </th>
                <th align="center">
                  <bold>
<italic>SF1*</italic>
</bold>
                </th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="left" valign="bottom">1<hr/></td>
                <td align="center" valign="bottom">15/21<hr/></td>
                <td align="center" valign="bottom">0.1<hr/></td>
                <td align="center" valign="bottom">0.6<hr/></td>
                <td align="center" valign="bottom">0.2<hr/></td>
                <td align="center" valign="bottom">1.0<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="bottom">2<hr/></td>
                <td align="center" valign="bottom">20/23<hr/></td>
                <td align="center" valign="bottom">8.6<hr/></td>
                <td align="center" valign="bottom">853<hr/></td>
                <td align="center" valign="bottom">2.1<hr/></td>
                <td align="center" valign="bottom">365<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="bottom">3<hr/></td>
                <td align="center" valign="bottom">24/25<hr/></td>
                <td align="center" valign="bottom">0.1<hr/></td>
                <td align="center" valign="bottom">99<hr/></td>
                <td align="center" valign="bottom">0.04<hr/></td>
                <td align="center" valign="bottom">6.3<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="bottom">4<hr/></td>
                <td align="center" valign="bottom">22/30<hr/></td>
                <td align="center" valign="bottom">5.0<hr/></td>
                <td align="center" valign="bottom">3214<hr/></td>
                <td align="center" valign="bottom">6.1<hr/></td>
                <td align="center" valign="bottom">259<hr/></td>
              </tr>
              <tr>
                <td align="left">Adrenal pool</td>
                <td align="center">&#xA0;</td>
                <td align="center">0.03</td>
                <td align="center">481</td>
                <td align="center">0</td>
                <td align="center">2462</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>*An adipose tissue pool was used as the reference sample in the expression analysis.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>The <italic>AR</italic> gene was overexpressed in myelolipomas from patients 2 and 4. Low <italic>AR</italic> expression levels were found in the other cases (patients 1 and 3). <italic>AR</italic> expression was correlated with <italic>LEP</italic> expression in all tumors.</p>
      </sec>
      <sec>
        <title>Clonality and nCAG repeat number analysis</title>
        <p>X-chromosome inactivation pattern analysis revealed a polyclonal origin in all tumors. In addition, all tumors were informative, and nCAG repeat numbers varied from 20 to 30, except in the tumor from patient 1, which had a short allele (15 repeats) (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>The pathogenesis of adrenal myelolipomas is unclear, but several mechanisms have been proposed to underlie the etiology. One of the hypothesis is that hematopoietic and fat elements could derive from common progenitor cells secondary to stimulatory factors [<xref ref-type="bibr" rid="B15">15</xref>]. In this study, we demonstrated that the <italic>MC2R</italic> gene was overexpressed in 3 out of 4 myelolipomas. Among these 3 cases, 1 giant bilateral myelolipoma was associated with CAH, and two patients presented sporadic myelolipomas. Chronic ACTH hyperstimulation has been proposed as the main hypothesis to explain the higher frequency of giant and bilateral myelolipomas in poor-compliance CAH patients, but it has never been previously demonstrated. Lack of <italic>MC2R</italic> gene expression was demonstrated in a giant adrenal myelolipoma associated with CAH employing a semi-quantitative approach to analyze mRNA expression [<xref ref-type="bibr" rid="B1">1</xref>]. Therefore, to our knowledge, our finding is the first evidence of <italic>MC2R</italic> overexpression in myelolipomas. <italic>MC2R</italic> overexpression was found in all but one case. Despite of chronic ACTH hyperstimulation, myelolipoma from patient 1 did not present <italic>MC2R</italic> overexpression.</p>
      <p>Androgen receptors have also been implicated in the pathogenesis of myelolipomas associated with poorly controlled CAH patients [<xref ref-type="bibr" rid="B1">1</xref>]. In the current study, <italic>AR</italic> overexpression was detected in 2 tumors: a giant bilateral myelolipoma in a CAH patient and a sporadic case. <italic>AR</italic> expression was previously assessed in a single case of bilateral myelolipoma associated with CAH using a semi-quantitative technique, but the results were negative [<xref ref-type="bibr" rid="B1">1</xref>]. Here, we employed a more sensitive approach to study <italic>AR</italic> and <italic>MC2R</italic> expression. The overexpression of <italic>AR</italic> and <italic>MC2R</italic> genes was concomitantly found in two of the cases.</p>
      <p>It has been postulated that androgens, through their interaction with androgen receptors, may play an important role in the development of specific tumors, such as ovarian and prostate cancer [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Exon 1 of the <italic>AR</italic> gene contains highly polymorphic trinucleotide repeats, and the length of the nCAG repeat segment is inversely correlated with the transactivation function of the <italic>AR</italic> gene [<xref ref-type="bibr" rid="B18">18</xref>]. Interestingly, the case of bilateral giant myelolipoma associated with CAH that lacked <italic>MC2R</italic> and <italic>AR</italic> overexpression had a shorter <italic>AR</italic> allele compared with the other tumors, suggesting that this <italic>AR</italic> genotype in the context of very high androgen levels may play a causative role in the development of myelolipomas. The stimulatory effect of <italic>MC2R</italic> and <italic>AR</italic> overexpression or increased <italic>AR</italic> transactivation activity in the development of adrenal myelolipomas could be reinforced by the finding of a polyclonal origin in all tumors described here.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>In conclusion, we first demonstrated here <italic>MC2R</italic> or <italic>AR</italic> overexpression in giant bilateral myelolipomas from poor-compliance CAH patients. Therefore, we can speculate that chronic ACTH and androgen stimulation may play a causative role in myelolipomas of poorly controlled CAH patients. In addition, X-chromosome inactivation pattern analysis revealed a polyclonal origin in all tumors, suggesting a stimulatory effect as a trigger for tumor development.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CAH: Congenital adrenal hyperplasia; ACTH: Adrenocorticotropic hormone; MC2R: Melanocortin 2 receptor; SF1: Steroidogenic factor 1; LEP: Leptin; AR: Androgen Receptor; ACTB: Beta-actin; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.</p>
    </sec>
    <sec>
      <title>Competing interest</title>
      <p>The authors declared that they have no competing interest.</p>
    </sec>
    <sec>
      <title>Author contribution</title>
      <p>MQA: data analysis, interpretation, drafting the manuscript. LCK: data acquisition, data analysis. LPB: data acquisition, data analysis, statistical analysis. AML: data acquisition, statistical analysis. BMP. Mariani: data acquisition, data analysis. MR: data acquisition, critical revision. OM: data acquisition, critical revision. FTD: performed the laparoscopic procedure of patients included in this study. BBM: critical revision, supervision. TASSB: conception and design, drafting the manuscript, critical revision, supervision. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6823/14/42/prepub">http://www.biomedcentral.com/1472-6823/14/42/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgments</title>
      <p>We thank Dr. Sandra M. Villares for providing the mRNA pool of adipose tissue used in this study.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hagiwara</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Usui</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kimura</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Tagami</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Naruse</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Minamiguchi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kato</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Okuno</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shimatsu</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Lack of ACTH and androgen receptor expression in a giant adrenal myelolipoma associated with 21-hydroxylase deficiency</article-title>
          <source>Endocr Pathol</source>
          <year>2008</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>122</fpage>
          <lpage>127</lpage>
          <pub-id pub-id-type="doi">10.1007/s12022-008-9034-2</pub-id>
          <pub-id pub-id-type="pmid">18618087</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mansmann</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Balk</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Rothberg</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miyachi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Bornstein</surname>
            <given-names>SR</given-names>
          </name>
          <article-title>The clinically inapparent adrenal mass: update in diagnosis and management</article-title>
          <source>Endocr Rev</source>
          <year>2004</year>
          <volume>25</volume>
          <issue>2</issue>
          <fpage>309</fpage>
          <lpage>340</lpage>
          <pub-id pub-id-type="doi">10.1210/er.2002-0031</pub-id>
          <pub-id pub-id-type="pmid">15082524</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hisamatsu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sakai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Tsuda</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shigematsu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kanetake</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Combined adrenal adenoma and myelolipoma in a patient with Cushing's syndrome: case report and review of the literature</article-title>
          <source>Int J Urol</source>
          <year>2004</year>
          <volume>11</volume>
          <issue>6</issue>
          <fpage>416</fpage>
          <lpage>418</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2042.2004.00815.x</pub-id>
          <pub-id pub-id-type="pmid">15157212</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Maschler</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Rosenmann</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ehrenfeld</surname>
            <given-names>EN</given-names>
          </name>
          <article-title>Ectopic functioning adrenocortico-myelolipoma in longstanding Nelson's syndrome</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>1979</year>
          <volume>10</volume>
          <issue>5</issue>
          <fpage>493</fpage>
          <lpage>497</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.1979.tb02106.x</pub-id>
          <pub-id pub-id-type="pmid">476979</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nermoen</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Rorvik</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Holmedal</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Hykkerud</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Fougner</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Svartberg</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Husebye</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Lovas</surname>
            <given-names>K</given-names>
          </name>
          <article-title>High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2011</year>
          <volume>75</volume>
          <issue>6</issue>
          <fpage>753</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2011.04151.x</pub-id>
          <pub-id pub-id-type="pmid">21689130</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>German-Mena</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Zibari</surname>
            <given-names>GB</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>SN</given-names>
          </name>
          <article-title>Adrenal myelolipomas in patients with congenital adrenal hyperplasia: review of the literature and a case report</article-title>
          <source>Endocr Pract</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>3</issue>
          <fpage>441</fpage>
          <lpage>447</lpage>
          <pub-id pub-id-type="doi">10.4158/EP10340.RA</pub-id>
          <pub-id pub-id-type="pmid">21324823</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ioannidis</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Papaemmanouil</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chatzopoulos</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Paraskevas</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Konstantara</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kotronis</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kakoutis</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Makrantonakis</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Giant bilateral symptomatic adrenal myelolipomas associated with congenital adrenal hyperplasia</article-title>
          <source>Pathol Oncol Res</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>3</issue>
          <fpage>775</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="doi">10.1007/s12253-010-9330-2</pub-id>
          <pub-id pub-id-type="pmid">21222246</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McGeoch</surname>
            <given-names>SC</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Krukowski</surname>
            <given-names>ZH</given-names>
          </name>
          <name>
            <surname>Bevan</surname>
            <given-names>JS</given-names>
          </name>
          <article-title>Giant bilateral myelolipomas in a man with congenital adrenal hyperplasia</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <issue>2</issue>
          <fpage>343</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2011-2373</pub-id>
          <pub-id pub-id-type="pmid">22238394</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mermejo</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Elias Junior</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Saggioro</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Tucci Junior</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Castro</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Moreira</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Elias</surname>
            <given-names>PC</given-names>
          </name>
          <article-title>Giant adrenal myelolipoma associated with 21-hydroxylase deficiency: unusual association mimicking an androgen-secreting adrenocortical carcinoma</article-title>
          <source>Arq Bras Endocrinol Metabol</source>
          <year>2010</year>
          <volume>54</volume>
          <issue>4</issue>
          <fpage>419</fpage>
          <lpage>424</lpage>
          <pub-id pub-id-type="doi">10.1590/S0004-27302010000400012</pub-id>
          <pub-id pub-id-type="pmid">20625655</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Plaut</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Myelolipoma in the adrenal cortex; myeloadipose structures</article-title>
          <source>Am J Pathol</source>
          <year>1958</year>
          <volume>34</volume>
          <issue>3</issue>
          <fpage>487</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="pmid">13533522</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Dean</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Myelolipoma of the adrenal gland</article-title>
          <source>Scott Med J</source>
          <year>1971</year>
          <volume>16</volume>
          <issue>12</issue>
          <fpage>513</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="pmid">5135108</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Livak</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Schmittgen</surname>
            <given-names>TD</given-names>
          </name>
          <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>
          <source>Methods</source>
          <year>2001</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>402</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
          <pub-id pub-id-type="pmid">11846609</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kaupert</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Billerbeck</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Brito</surname>
            <given-names>VN</given-names>
          </name>
          <name>
            <surname>Mendonca</surname>
            <given-names>BB</given-names>
          </name>
          <name>
            <surname>Bachega</surname>
            <given-names>TA</given-names>
          </name>
          <article-title>Could the leukocyte x chromosome inactivation pattern be extrapolated to hair bulbs?</article-title>
          <source>Horm Res Paediatr</source>
          <year>2010</year>
          <volume>73</volume>
          <issue>4</issue>
          <fpage>238</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="doi">10.1159/000284387</pub-id>
          <pub-id pub-id-type="pmid">20215769</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rocha</surname>
            <given-names>RO</given-names>
          </name>
          <name>
            <surname>Billerbeck</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Pinto</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Melo</surname>
            <given-names>KF</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Longui</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Mendonca</surname>
            <given-names>BB</given-names>
          </name>
          <name>
            <surname>Bachega</surname>
            <given-names>TA</given-names>
          </name>
          <article-title>The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2008</year>
          <volume>68</volume>
          <issue>2</issue>
          <fpage>226</fpage>
          <lpage>232</lpage>
          <pub-id pub-id-type="pmid">17803691</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Selye</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Stone</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Hormonally induced transformation of adrenal into myeloid tissue</article-title>
          <source>Am J Pathol</source>
          <year>1950</year>
          <volume>26</volume>
          <issue>2</issue>
          <fpage>211</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="pmid">15406252</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kim</surname>
            <given-names>SC</given-names>
          </name>
          <name>
            <surname>Ju</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Mahavni</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Geisler</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Buller</surname>
            <given-names>RE</given-names>
          </name>
          <article-title>CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer</article-title>
          <source>Int J Gynecol Cancer</source>
          <year>2006</year>
          <volume>16</volume>
          <issue>Suppl 1</issue>
          <fpage>190</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">16515589</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gururajan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Posadas</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>LW</given-names>
          </name>
          <article-title>Future perspectives of prostate cancer therapy</article-title>
          <source>Transl Androl Urol</source>
          <year>2012</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>19</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">22773967</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wu</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Chou</surname>
            <given-names>YC</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>You</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>CA</given-names>
          </name>
          <article-title>Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility</article-title>
          <source>Eur J Cancer Prev</source>
          <year>2008</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>317</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="doi">10.1097/CEJ.0b013e3282f75e7f</pub-id>
          <pub-id pub-id-type="pmid">18562955</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
